![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://i1.rgstatic.net/publication/354109051_Safety_and_efficacy_of_tenecteplase_versus_alteplase_in_patients_with_acute_ischaemic_stroke_TRACE_a_multicentre_randomised_open_label_blinded-endpoint_PROBE_controlled_phase_II_study/links/61259ee40c2bfa282a6b47a9/largepreview.png)
PDF) Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded- endpoint (PROBE) controlled phase II study
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://www.dovepress.com/getfile_article_fulltext.php?filename=article_fulltext%2Fs360000%2F360967/img/NDT_A_360967_t0003_1.jpg)
Tenecteplase in Ischemic Stroke
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://www.j-stroke.org/upload//thumbnails/jos-2022-02880f3.gif)
Journal of Stroke
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://www.j-stroke.org/upload//thumbnails/jos-2022-02880f1.gif)
Journal of Stroke
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/f01638ef-74b6-4234-8ca2-f878bef67f7e/gr3_lrg.jpg)
Thrombolysis for acute ischaemic stroke: current status and future perspectives - The Lancet Neurology
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://i.ytimg.com/vi/rDzxwVjtj3k/maxresdefault.jpg)
Alteplase Archives - REBEL EM - Emergency Medicine Blog
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/b7cc80b5-3781-4be1-8f76-22da9b887273/gr2_lrg.jpg)
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial - The Lancet
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://www.dovepress.com/getfile_article_fulltext.php?filename=article_fulltext%2Fs360000%2F360967/img/NDT_A_360967_t0001.jpg)
Tenecteplase in Ischemic Stroke
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2018/nejm_2018.378.issue-17/nejmoa1716405/20180502/images/img_medium/nejmoa1716405_t1.jpeg)
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://i1.rgstatic.net/publication/330116531_Tenecteplase_Versus_Alteplase_Between_3_and_45_Hours_in_Low_National_Institutes_of_Health_Stroke_Scale/links/6103a1e00c2bfa282a0d8c07/largepreview.png)
PDF) Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://www.ahajournals.org/cms/asset/c9b29dff-f0b6-4744-bee0-c28673b50586/strokeaha.122.038950.fig02.jpg)
Prospective Observational Cohort Study of Tenecteplase Versus Alteplase in Routine Clinical Practice
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/4acf6860-8060-4075-9709-cad2dd9ec5c9/gr4_lrg.jpg)
Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study - The Lancet Neurology
![Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial - The Lancet Neurology](https://image.slidesharecdn.com/journalclubnortesttrial-171021065107/85/journal-club-nortest-trial-2-320.jpg?cb=1667349689)
Journal club nortest trial